From a clinical perspective, elevated SHCBP1 expression is associated with poor prognosis, including higher tumor grade, lymphovascular invasion, and diminished overall and disease-free survival across diverse cancer types such as breast cancer, lung adenocarcinoma, HCC, glioblastoma, and gastric cancer. This evidence concerns the gene SHCBP1 and glioblastoma.